You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!
Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Seeking AlphaMay 9
Regulus Therapeutics reports Q1 results
Regulus Therapeutics (NASDAQ:RGLS): Q1 GAAP EPS of -$0.31. Alliance revenue of $6.78M. Cash and cash equivalents of $10.3M; also in May 2019, closed first tranche of its $41.8M private placement and received net proceeds of ~$15.7M Press Release...
Yahoo FinanceMay 9
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Engagement with FDA on RGLS4326 Clinical Program Ongoing LA JOLLA, Calif., May 9, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarte...
Expected Aug 8, After Hours